New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
03 oct. 2022 08h00 HE
|
Daxor Corporation
Presented at Key Scientific Society Meeting -Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America
26 sept. 2022 08h00 HE
|
Daxor Corporation
Compelling New Patient Outcome Data to be Presented Oak Ridge, TN, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 17h05 HE
|
Daxor Corporation
Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
29 août 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter...
Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022
25 août 2022 16h05 HE
|
Daxor Corporation
Conference Call to be held today at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
24 août 2022 16h40 HE
|
Daxor Corporation
Conference Call to be held on the same day at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
27 juil. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today an unaudited increase of 49.4% in sales of...
DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
21 juil. 2022 08h00 HE
|
Daxor Corporation
Daxor Has Exclusive Access to the Cardiovascular Industry's Most Comprehensive and Powerful Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically...
DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE
18 juil. 2022 08h00 HE
|
Daxor Corporation
Company Received Funding from NIH to Accelerate New Clinical Decision Support Software For Use With Daxor’s Blood Volume Analyzer for Heart Failure Treatment Oak Ridge, TN, July 18, 2022 (GLOBE...
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
27 juin 2022 08h00 HE
|
Daxor Corporation
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...